CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

CytoDyn Releases ESMO Breast Cancer Meeting Poster
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
March 2025 Letter to Shareholders
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
December 2024 Letter to Shareholders
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.